STOCK TITAN

Camp4 Therapeutics: Vivo reports 9.99% ownership

Available on EDGAR Accepted by SEC EDGAR Learn about SEC filing dates
(Neutral)

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

Form Type
SCHEDULE 13G/A

Rhea-AI Filing Summary

For Camp4 Therapeutics (CAMP), Vivo Opportunity Fund Holdings, L.P. reports beneficial ownership of 7,906,436 shares, comprising 5,071,824 common shares and 2,834,612 shares issuable upon exercise of pre-funded warrants. Its general partner, Vivo Opportunity, LLC, reports the same position.

Vivo Opportunity Cayman Fund, L.P. reports beneficial ownership of 798,610 shares, comprising 512,287 common shares and 286,323 shares issuable upon exercise of pre-funded warrants. Its general partner, Vivo Opportunity Cayman, LLC, reports the same position. Each fund group's position is reported as 9.99%, based on 62,754,200 CAMP shares outstanding as of November 4, 2026. The warrant amounts reflect full exercise without giving effect to provisions that prevent exercise if it would result in the holder or its affiliates exceeding 9.99%.

Beneficial ownership 7,906,436 shares Vivo Opportunity Fund Holdings, L.P.; includes common shares and shares issuable upon exercise of pre-funded warrants
Common shares 5,071,824 shares Held of record by Vivo Opportunity Fund Holdings, L.P.
Shares issuable under pre-funded warrants 2,834,612 shares Included in Vivo Opportunity Fund Holdings, L.P.'s reported beneficial ownership; full exercise amount before the blocking provisions
Beneficial ownership 798,610 shares Vivo Opportunity Cayman Fund, L.P.; includes common shares and shares issuable upon exercise of pre-funded warrants
Common shares 512,287 shares Held of record by Vivo Opportunity Cayman Fund, L.P.
Shares issuable under pre-funded warrants 286,323 shares Included in Vivo Opportunity Cayman Fund, L.P.'s reported beneficial ownership; full exercise amount before the blocking provisions
Shares outstanding 62,754,200 shares CAMP shares outstanding as of November 4, 2026
Reported beneficial ownership percentage 9.99% Reported for each fund group
pre-funded warrants financial
"shares issuable upon exercise of certain pre-funded warrants"
Pre-funded warrants are financial instruments that give investors the right to purchase a company's stock at a set price, but with most or all of the purchase price paid upfront. They function like a coupon or gift card for stock, allowing investors to buy shares later at a fixed price, which can be beneficial if they want to avoid future price increases. This makes them important for investors seeking flexibility and certainty in their investment plans.
blocking provisions technical
"provisions preventing such warrants from being exercised"
beneficially own regulatory
"may be deemed to beneficially own an aggregate"
Beneficially own means having the economic rights and risks of a security—such as the right to receive dividends, sell the shares, or profit from price changes—whether or not your name appears on the official share register. Think of it like renting a car: you use it and reap the benefits even if the title lists someone else. Investors care because beneficial ownership determines who truly controls value, must be disclosed under securities rules, and can signal potential influence or trading activity that affects a stock’s price.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How many CAMP shares does Vivo Opportunity report?

Vivo Opportunity Fund Holdings, L.P. reports beneficial ownership of 7,906,436 shares, including 5,071,824 common shares and 2,834,612 shares issuable under pre-funded warrants. Vivo Opportunity Cayman Fund, L.P. reports 798,610 shares, including 512,287 common shares and 286,323 warrant shares. Each fund's general partner reports the same position; both positions are stated as 9.99%. The warrant amounts reflect full exercise without giving effect to the blocking provisions.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google





13463J101

(CUSIP Number)
09/30/2026

(Date of Event Which Requires Filing of this Statement)


Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
Rule 13d-1(b)
Rule 13d-1(c)
Rule 13d-1(d)




schemaVersion:


SCHEDULE 13G




Comment for Type of Reporting Person: The number represents an aggregate of (i) 5,071,824 shares of common stock, $0.0001 par value (the "Common Stock") of CAMP4 Therapeutics Corporation (the "Issuer"), and (ii) 2,834,612 shares of Common Stock issuable upon exercise of certain pre-funded warrants. All securities are held of record by Vivo Opportunity Fund Holdings, L.P. Vivo Opportunity, LLC is the general partner of Vivo Opportunity Fund Holdings, L.P. The percentage is based on 62,754,200 shares of Common Stock of the Issuer outstanding as of November 4, 2026, as reported in the Issuer's Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission ("SEC") on November 5, 2026. The pre-funded warrants contain provisions preventing such warrants from being exercised into shares of Common Stock, if such exercise would result in the holder or its affiliates obtaining greater than 9.99% of the Issuer's voting securities. However, the amounts reported in rows 5, 7 and 9 herein represent the number of shares of Common Stock that would be issuable upon full exercise of the pre-funded warrants, without giving effect to the blocking provisions.


SCHEDULE 13G




Comment for Type of Reporting Person: The number represents an aggregate of (i) 5,071,824 shares of Common Stock of the Issuer, and (ii) 2,834,612 shares of Common Stock issuable upon exercise of certain pre-funded warrants. All securities are held of record by Vivo Opportunity Fund Holdings, L.P. Vivo Opportunity, LLC is the general partner of Vivo Opportunity Fund Holdings, L.P. The percentage is based on 62,754,200 shares of Common Stock of the Issuer outstanding as of November 4, 2026, as reported in the Issuer's Quarterly Report on Form 10-Q filed with the SEC on November 5, 2026. The pre-funded warrants contain provisions preventing such warrants from being exercised into shares of Common Stock, if such exercise would result in the holder or its affiliates obtaining greater than 9.99% of the Issuer's voting securities. However, the amounts reported in rows 5, 7 and 9 herein represent the number of shares of Common Stock that would be issuable upon full exercise of the pre-funded warrants, without giving effect to the blocking provisions.


SCHEDULE 13G




Comment for Type of Reporting Person: The number represents an aggregate of (i) 512,287 shares of Common Stock of the Issuer, and (ii) 286,323 shares of Common Stock issuable upon exercise of certain pre-funded warrants. All securities are held of record by Vivo Opportunity Cayman Fund, L.P. Vivo Opportunity Cayman, LLC is the general partner of Vivo Opportunity Cayman Fund, L.P. The percentage is based on 62,754,200 shares of Common Stock of the Issuer outstanding as of November 4, 2026, as reported in the Issuer's Quarterly Report on Form 10-Q filed with the SEC on November 5, 2026. The pre-funded warrants contain provisions preventing such warrants from being exercised into shares of Common Stock, if such exercise would result in the holder or its affiliates obtaining greater than 9.99% of the Issuer's voting securities. However, the amounts reported in rows 5, 7 and 9 herein represent the number of shares of Common Stock that would be issuable upon full exercise of the pre-funded warrants, without giving effect to the blocking provisions.


SCHEDULE 13G




Comment for Type of Reporting Person: The number represents an aggregate of (i) 512,287 shares of Common Stock of the Issuer, and (ii) 286,323 shares of Common Stock issuable upon exercise of certain pre-funded warrants. All securities are held of record by Vivo Opportunity Cayman Fund, L.P. Vivo Opportunity Cayman, LLC is the general partner of Vivo Opportunity Cayman Fund, L.P. The percentage is based on 62,754,200 shares of Common Stock of the Issuer outstanding as of November 4, 2026, as reported in the Issuer's Quarterly Report on Form 10-Q filed with the SEC on November 5, 2026. The pre-funded warrants contain provisions preventing such warrants from being exercised into shares of Common Stock, if such exercise would result in the holder or its affiliates obtaining greater than 9.99% of the Issuer's voting securities. However, the amounts reported in rows 5, 7 and 9 herein represent the number of shares of Common Stock that would be issuable upon full exercise of the pre-funded warrants, without giving effect to the blocking provisions.


SCHEDULE 13G



Vivo Opportunity Fund Holdings, L.P.
Signature:/s/ Kevin Dai
Name/Title:Kevin Dai/Managing Member of Vivo Opportunity, LLC, General Partner
Date:11/16/2026
Vivo Opportunity, LLC
Signature:/s/ Kevin Dai
Name/Title:Kevin Dai/Managing Member
Date:11/16/2026
Vivo Opportunity Cayman Fund, L.P.
Signature:/s/ Kevin Dai
Name/Title:Kevin Dai/Managing Member of Vivo Opportunity Cayman, LLC, General Partner
Date:11/16/2026
Vivo Opportunity Cayman, LLC
Signature:/s/ Kevin Dai
Name/Title:Kevin Dai/Managing Member
Date:11/16/2026

Keep reading